111 related articles for article (PubMed ID: 37311033)
1. Delayed engagement of host defenses enables SARS-CoV-2 viremia and productive infection of distal organs in the hamster model of COVID-19.
Carrau L; Frere JJ; Golynker I; Fajardo A; Rivera CF; Horiuchi S; Roonprapunt T; Minkoff JM; Blanco-Melo D; TenOever B
Sci Signal; 2023 Jun; 16(789):eadg5470. PubMed ID: 37311033
[TBL] [Abstract][Full Text] [Related]
2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
3. Innate immune evasion strategies of SARS-CoV-2.
Minkoff JM; tenOever B
Nat Rev Microbiol; 2023 Mar; 21(3):178-194. PubMed ID: 36631691
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
Front Immunol; 2022; 13():888897. PubMed ID: 35663932
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pathogenesis of SARS-CoV-2 infection in K18-hACE2 mouse and Syrian golden hamster models.
Jeong H; Woo Lee Y; Park IH; Noh H; Kim SH; Kim J; Jeon D; Jang HJ; Oh J; On D; Uhm C; Cho K; Oh H; Yoon S; Seo JS; Kim JJ; Seok SH; Lee YJ; Hong SM; An SH; Yeon Kim S; Kim YB; Hwang JY; Lee HJ; Kim HB; Jeong DG; Song D; Song M; Park MS; Choi KS; Park JW; Seo JY; Yun JW; Shin JS; Lee HY; Nam KT; Seong JK
Dis Model Mech; 2022 Nov; 15(11):. PubMed ID: 36222118
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2.
Beyer DK; Forero A
J Mol Biol; 2022 Mar; 434(6):167265. PubMed ID: 34562466
[TBL] [Abstract][Full Text] [Related]
7. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts.
Guarnieri JW; Dybas JM; Fazelinia H; Kim MS; Frere J; Zhang Y; Soto Albrecht Y; Murdock DG; Angelin A; Singh LN; Weiss SL; Best SM; Lott MT; Zhang S; Cope H; Zaksas V; Saravia-Butler A; Meydan C; Foox J; Mozsary C; Bram Y; Kidane Y; Priebe W; Emmett MR; Meller R; Demharter S; Stentoft-Hansen V; Salvatore M; Galeano D; Enguita FJ; Grabham P; Trovao NS; Singh U; Haltom J; Heise MT; Moorman NJ; Baxter VK; Madden EA; Taft-Benz SA; Anderson EJ; Sanders WA; Dickmander RJ; Baylin SB; Wurtele ES; Moraes-Vieira PM; Taylor D; Mason CE; Schisler JC; Schwartz RE; Beheshti A; Wallace DC
Sci Transl Med; 2023 Aug; 15(708):eabq1533. PubMed ID: 37556555
[TBL] [Abstract][Full Text] [Related]
8. Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases.
Nayak B; Lal G; Kumar S; Das CJ; Saraya A; Shalimar
Front Cell Infect Microbiol; 2021; 11():753249. PubMed ID: 34760721
[TBL] [Abstract][Full Text] [Related]
9. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
[TBL] [Abstract][Full Text] [Related]
10. Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes.
Castellan M; Zamperin G; Franzoni G; Foiani G; Zorzan M; Drzewnioková P; Mancin M; Brian I; Bortolami A; Pagliari M; Oggiano A; Vascellari M; Panzarin V; Crovella S; Monne I; Terregino C; De Benedictis P; Leopardi S
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851642
[TBL] [Abstract][Full Text] [Related]
11. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.
Boechat JL; Chora I; Morais A; Delgado L
Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315
[TBL] [Abstract][Full Text] [Related]
12. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
[TBL] [Abstract][Full Text] [Related]
13. Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of IFN-mediated innate immune defenses.
Herder V; Dee K; Wojtus JK; Epifano I; Goldfarb D; Rozario C; Gu Q; Da Silva Filipe A; Nomikou K; Nichols J; Jarrett RF; Stevenson A; McFarlane S; Stewart ME; Szemiel AM; Pinto RM; Masdefiol Garriga A; Davis C; Allan J; Graham SV; Murcia PR; Boutell C
PLoS Biol; 2021 Dec; 19(12):e3001065. PubMed ID: 34932557
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model.
Chen YT; Chang YH; Pathak N; Tzou SC; Luo YC; Hsu YC; Li TN; Lee JY; Chen YC; Huang YW; Yang HJ; Hsu NY; Tsai HP; Chang TY; Hsu SC; Liu PC; Chin YF; Lin WC; Yang CM; Wu HL; Lee CY; Hsu HL; Liu YC; Chu JW; Wang LH; Wang JY; Huang CH; Lin CH; Hsieh PS; Wu Lee YH; Hung YJ; Yang JM
Front Immunol; 2022; 13():1080897. PubMed ID: 36618412
[TBL] [Abstract][Full Text] [Related]
15. The Host Response to Influenza A Virus Interferes with SARS-CoV-2 Replication during Coinfection.
Oishi K; Horiuchi S; Minkoff JM; tenOever BR
J Virol; 2022 Aug; 96(15):e0076522. PubMed ID: 35862681
[TBL] [Abstract][Full Text] [Related]
16. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
17. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.
Chiba S; Kiso M; Nakajima N; Iida S; Maemura T; Kuroda M; Sato Y; Ito M; Okuda M; Yamada S; Iwatsuki-Horimoto K; Watanabe T; Imai M; Armbrust T; Baric RS; Halfmann PJ; Suzuki T; Kawaoka Y
mBio; 2021 Feb; 13(1):e0304421. PubMed ID: 35100870
[TBL] [Abstract][Full Text] [Related]
18. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity.
Hoagland DA; Møller R; Uhl SA; Oishi K; Frere J; Golynker I; Horiuchi S; Panis M; Blanco-Melo D; Sachs D; Arkun K; Lim JK; tenOever BR
Immunity; 2021 Mar; 54(3):557-570.e5. PubMed ID: 33577760
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.
Plante KS; Dwivedi V; Plante JA; Fernandez D; Mirchandani D; Bopp N; Aguilar PV; Park JG; Tamayo PP; Delgado J; Shivanna V; Torrelles JB; Martinez-Sobrido L; Matos R; Weaver SC; Sastry KJ; Newman RA
Biomed Pharmacother; 2021 Jun; 138():111457. PubMed ID: 33721754
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
